Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25688112 | 0.90 | TLR8 (0.69) | TLR8TLR7 | |
| SCHEMBL18659723 | 0.89 | TLR8 (0.68) | TLR8TLR7 | |
| SCHEMBL28472239 | 0.89 | TLR8 (0.69) | TLR8TLR7 | |
| SCHEMBL18041313 | 0.88 | TLR8 (0.67) | TLR8TLR7 | |
| SCHEMBL22538803 | 0.87 | TLR8 (0.66) | TLR8TLR7 | |
| SCHEMBL18041391 | 0.87 | TLR8 (0.66) | TLR8TLR7 | |
| SCHEMBL1798834 | 0.86 | TLR8 (0.55) | TLR8TLR7 | |
| SCHEMBL2333056 | 0.86 | TLR8 (0.51) | TLR8TLR7 | |
| SCHEMBL21912241 | 0.85 | TLR8 (0.72) | TLR8TLR7 | |
| SCHEMBL25688116 | 0.85 | TLR8 (0.65) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109944-A1 | TLR MODULATOR AND USE THEREOF | 映恩生物制药（苏州）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| EP-3949969-A2 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | Silverback Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3595668-B1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS INC (US) | 2021-07-21 | — | — | EP | disclosed |
| CN-108055842-B | Sulfinylphenyl or sulfonimidoylphenyl benzazepine idle | 豪夫迈·罗氏有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-107148417-B | Benzazepine sulfonamide compounds | 豪夫迈·罗氏有限公司 | 2020-09-08 | — | — | CN | disclosed |
| WO-2020056198-A2 | SUBSTITUTED BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020056008-A1 | COMPOSITIONS FOR THE TREATMENT OF DISEASE WITH IMMUNE STIMULATORY CONJUGATES | SILVERBACK THERAPEUTICS, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| EP-3350168-B1 | SULFINYLPHENYL OR SULFONIMIDOYLPHENYL BENZAZEPINES | HOFFMANN LA ROCHE (CH) | 2019-12-18 | — | — | EP | disclosed |
| EP-3350168-B1 | SULFINYLPHENYL OR SULFONIMIDOYLPHENYL BENZAZEPINES | HOFFMANN LA ROCHE (CH) | 2019-12-18 | — | — | EP | disclosed |
| US-10428027-B2 | Sulfinylphenyl or sulfonimidoylphenyl benzazepines | HOFFMANN LA-ROCHE INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3350168-A1 | SULFINYLPHENYL OR SULFONIMIDOYLPHENYL BENZAZEPINES | H. Hoffnabb-La Roche Ag (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-20180194735-A1 | Sulfinylphenyl or Sulfonimidoylphenyl Benzazepines | HOFFMANN LA-ROCHE INC. (US) | 2018-07-12 | — | — | US | disclosed |
| US-9890124-B2 | Benzazepine sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3233835-A1 | BENZAZEPINE SULFONAMIDE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| US-20170275253-A1 | BENZAZEPINE SULFONAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275253-A1 | BENZAZEPINE SULFONAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-09-28 | — | — | US | disclosed |
| WO-2017046112-A1 | SULFINYLPHENYL OR SULFONIMIDOYLPHENYL BENZAZEPINES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046112-A1 | SULFINYLPHENYL OR SULFONIMIDOYLPHENYL BENZAZEPINES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-23 | — | — | WO | disclosed |
| WO-2016096778-A1 | BENZAZEPINE SULFONAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096778-A1 | BENZAZEPINE SULFONAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275253-A1 | BENZAZEPINE SULFONAMIDE COMPOUNDS | TLR8, TLR7, TLR5 | TLR8 1/4885TLR7 2/4885 |
| US-10428027-B2 | Sulfinylphenyl or sulfonimidoylphenyl benzazepines | TLR1, TLR4, TLR5 | TLR8 9/4885TLR7 8/4885 |
| US-20180194735-A1 | Sulfinylphenyl or Sulfonimidoylphenyl Benzazepines | TLR1, TLR4, TLR5 | TLR8 9/4885TLR7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.